pharmaphorum

MAY 12, 2021

UK biotech MiNA Therapeutics has signed up another big pharma partner for its small activating RNA (saRNA) platform, which upregulates the activity of proteins, with Eli Lilly the latest to get in on the action. . The post Lilly buys into MiNA’s protein-boosting RNA tech in $1.25bn deal appeared first on.

RNA 60

RNA Protein Drugs Pharma Companies 60

The Pharma Data

DECEMBER 20, 2020

UK drug developer Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial. . SN14 works by targeting the coronavirus’ nucleocapsid and spike proteins to prevent viral replication using the company’s ImmunoBody DNA vaccine technology.

Clinical Trials 52

Clinical Trials Clinical Trials Pharma Companies Vaccination 52

BioPharma Reporter

JULY 31, 2023

Boston-based pharma company Ratio Therapeutics has initiated dosing in a phase 1 study evaluating the pharmacokinetics, biodistribution and radiation dosimetry of a novel fibroblast activation protein-alpha (FAP)-targeted radiopharmaceutical, RTX-1363S, for PET imaging in adult healthy volunteers.

Pharma Companies 52

Pharma Companies Protein Development 52

Delveinsight

SEPTEMBER 3, 2021

Thus, missed or late diagnosis is a serious concern; however, it can be due to the heterogeneity of the condition, late age of onset of symptoms, slow and gradual development of symptoms, and so on. Additionally, a lack of curative and approved therapies in the CMT disease market is a serious unmet need.

Pharma Companies 52

Pharma Companies Marketing Clinical Trials Clinical Trials 52

Drug Discovery World

OCTOBER 6, 2022

With key players including AstraZeneca, Bayer, Novartis and Pfizer pushing the boundaries of drug development, the reason behind this growth is evident. According to McKinsey & Company: “Europe’s complex biotech landscape comprises hundreds of companies, dozens of countries, and multiple paths to innovation and financing… .

Development 52

Development Drugs Life Science Marketing 52

pharmaphorum

MARCH 11, 2022

After a period where vaccine development had fallen away, suddenly it is back in the limelight. However, for those individuals working on vaccine development, the pandemic has proven to be a validation of the important work being carried out in the field. There are very few things to be grateful for about the arrival of the pandemic.

Vaccination 80

Vaccination Vaccine Development Manufacturing 80

pharmaphorum

JANUARY 12, 2023

In this case, the technology will be used to aid computer-aided drug discovery (CADD) – an approach that has been around for decades, but is being transformed by quantum chemistry techniques – and specifically to model the interactions between proteins and their ligands in silico.

Drugs 118

Drugs Protein Pharma Companies Sales 118

pharmaphorum

AUGUST 18, 2020

Could AI prevent future pandemics by developing an armoury of drugs that work against all coronaviruses? This is a question that a consortium of European pharma companies hopes to answer as it aims to rapidly develop new therapies to combat the pandemic. But also included in the 77.7

Protein 97

Protein Pharma Companies RNA Drugs 97

Drug Discovery World

JANUARY 21, 2024

Advances in this area are having a positive effect on both the commercial success of drug discovery and development organisations, as well as benefitting the health and wellbeing of the global population. Technology plays multiple roles in all stages of vaccine development,” says Kanekiyo. “It Is pharma’s commercial model dying?

Protein 52

Protein Vaccination Vaccine Development 52

Drug Discovery World

FEBRUARY 23, 2023

Spanish pharma company Ferrer and Swiss biotech Asceneuron have signed a licensing agreement giving Ferrer the rights to ASN90 in progressive supranuclear palsy (PSP), an orphan, tau-related disease with a high unmet medical need. The disease gets progressively worse, causing severe disability within three to five years of onset.

Drugs 52

Drugs Licensing Licensing Protein 52

pharmaphorum

FEBRUARY 16, 2021

Inflammasomes are a group of intracellular proteins associated with the inflammatory response, and prior research has linked the NLRP3 inflammasome to the aggregation of amyloid beta and tau protein – which together form the characteristic plaques and tangles in the brains of AD patients.

Research 117

Research Drugs Protein Development 117

pharmaphorum

NOVEMBER 23, 2021

Sanofi has bolstered its push into mRNA-based therapies with a new licensing deal – but not as might be expected with some up-and-coming biotech company. Sanofi is the first pharma company to partner with Baidu on its LinearDesign AI platform, which has been developed specifically to optimise the sequence of mRNA-based vaccines and drugs.

Licensing 101

Licensing Licensing Vaccination Vaccine 101

Pharmaceutical Technology

FEBRUARY 13, 2023

Gene therapies are an attractive way of targeting the underlying genetic mutations, but traditional approaches cannot be used while targeting mutations for Dravet Syndrome, forcing researchers to develop new ways. To tackle this, companies have developed different ways to focus on the gene.

Research 264

Research Gene Gene Therapy Genome 264

Drug Discovery World

NOVEMBER 15, 2022

Known for its ability to offer precision and flexibility while expanding the experimental scale, synthetic biology tools can reduce development timelines and costs, and lend a competitive advantage over traditional methods. . Here we outline four synthetic biology approaches that are improving and accelerating drug discovery: .

DNA 98

DNA Drugs Antibody Engineer 98

pharmaphorum

JANUARY 18, 2022

Two Spanish pharma companies are joining forces to identify new oral treatments for immune-inflammatory skin diseases with high unmet medical needs. Researchers at Almirall have identified several proteins whose abnormal function is associated with inflammatory immune skin diseases.

Dermatology 52

Dermatology Protein Pharma Companies Research 52

pharmaphorum

APRIL 21, 2022

One of the leading companies in the bid to bring a new class of alpha-synuclein targeting drugs to market for Parkinson’s disease – AbbVie – is ducking out of the challenge. ” She added that BioArctic will now “investigate options to continue the development of this asset.”

Antibody 82

Antibody Protein Gene Therapy Pharma Companies 82

Pharmaceutical Technology

APRIL 24, 2023

“Biologics products may contain proteins that control the action of other proteins and cellular processes, genes that control production of vital proteins, modified human hormones, or cells that produce substances that suppress or activate components of the immune system.

Contract Manufacturing 130

Contract Manufacturing Manufacturing Protein Sales 130

pharmaphorum

AUGUST 7, 2020

It is part of a five-point plan by Pfizer launched in March that urged all pharma companies and biotechs to work together with government agencies and academic institutions to tackle the COVID-19 pandemic. Pfizer will provide contract manufacturing services at its facility in McPherson, Kansas, to supply the drug to Gilead.

Manufacturing 106

Manufacturing Contract Manufacturing Protein Allergies 106

pharmaphorum

JANUARY 10, 2022

On the back of the approvals for Pfizer/BioNTech and Moderna, suddenly there is a large amount of interest from big pharma companies to get involved in the mRNA space. The company has also stated, at the same time as the study was announced, that it will look at developing mRNA technology in oncology and genetic diseases.

RNA 99

RNA Vaccination Vaccine Pharma Companies 99

Drug Discovery World

JANUARY 3, 2023

Most major pharma companies operate DEL platforms, and several service providers offer DEL capabilities to companies that outsource their DEL activities. protease or kinase inhibitors) or protein-protein interactions (e.g., Targeted protein degradation and related modalities. cytokine-receptor disrupters).

DNA 52

DNA Protein Drugs RNA 52

pharmaphorum

FEBRUARY 9, 2022

However, the industry is constantly looking to discover the next frontier in treatment development and technology to provide more effective, safer treatments to patients. One area that is gathering increasing levels of interest is the development of cancer vaccines. A broad front. A broad front. Prior success.

Vaccination 123

Vaccination Vaccine Clinical Trials Clinical Trials 123

The Pharma Data

SEPTEMBER 29, 2020

The collaboration has leveraged Sosei’s StaR technology and Structure-based Drug Design (SBDD) capabilities to design oral small molecules that modulate different G protein-coupled receptor (GPCR) targets across multiple disease areas.

Clinical Trials 52

Clinical Trials Clinical Trials Pharma Companies Trials 52

pharmaphorum

FEBRUARY 14, 2022

The pandemic also saw a reduction in the overall development cycle of a product, which has been growing in recent years. In 2020, the development cycle averaged 7.14 This can be understood through the accelerated development cycles experienced on COVID-19 treatments and vaccines. years, which was reduced during 2021 to 6.9

Production 94

Production Clinical Trials Clinical Trials Sales 94

XTalks

MAY 29, 2024

Here, we will deep-dive into the top five fastest growing pharma and biotech companies in 2024, showcasing their innovative strategies and inspiring achievements. Pfizer (Overall Rank 268) Leading the list is one of the most renowned pharma companies in the world: Pfizer. Vertex is growing at a CAGR of 28.97

Medicine 52

Medicine Marketing FDA Approval Development 52

pharmaphorum

AUGUST 23, 2021

Pfizer is the latest big pharma company to take a position on drugs that target CD47 – a ‘don’t eat me’ signal that protects cancer cells from being attacked by the immune system. The drugmaker has agreed a $2.3 The drugmaker has agreed a $2.3

Protein 57

Protein Pharma Companies Clinical Trials Clinical Trials 57

XTalks

OCTOBER 22, 2020

Pharmaceutical development of novel drugs is a complex and tedious process. To achieve transparency and actionability of data, pharmaceutical companies are evolving their manufacturing processes by digitalizing the data from all of their equipment. Nevertheless, they have succeeded to continue the process development to the next stage.

Manufacturing 98

Manufacturing Development Production Gene Therapy 98

The Pharma Data

JANUARY 24, 2021

.–( BUSINESS WIRE )– Faze Medicines , a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates, today announced that it has appointed Philip Vickers, Ph.D., a company developing first-in-class therapeutic antibodies targeting the tumor microenvironment.

Medicine 52

Medicine Pharma Companies Gene Therapy Development 52

pharmaphorum

OCTOBER 12, 2022

Overall, the aim is to improve the efficiency of drug discovery by identifying genetic variants that contribute to human disease in omics data – a broad category that includes DNA profiles, gene transcripts, and protein expression.

Genome 62

Genome Genomics DNA Drugs 62

pharmaphorum

NOVEMBER 23, 2020

The pharma company, known as MSD outside North America, will pay the money up front with OncoImmune shareholders receiving further undisclosed milestone payments if certain sales and regulatory goals are achieved. It has been studied in GVHD in phase 2 clinical trials, and a pivotal phase 3 clinical trial has already begun in GVHD.

Drugs 62

Drugs Clinical Trials Clinical Trials Trials 62

pharmaphorum

FEBRUARY 28, 2022

Studies have suggested that some patients with COVID-19 exhibit marked increases in autoantibody reactivities as compared to uninfected individuals, including some that seem to target immune components like cytokines, chemokines and complement proteins. Financial terms of the contract have not been disclosed. million ($1.9 million ($1.9

Life Science 52

Life Science Pharma Companies Development Protein 52

pharmaphorum

DECEMBER 8, 2020

AbCellera is a specialist in applying artificial intelligence to drug discovery, specifically to sift through immune system data to find antibodies that can be developed as drugs. Its approach involves licensing rights to the antibodies to other pharma companies, rather than bringing its own candidates through development.

Drugs 99

Drugs Antibody FDA Approval Pharma Companies 99

pharmaphorum

MARCH 9, 2021

Last year, Belgium’s ExeVir Bio raised 23 million euros ($27 million) to finance development of llama antibodies – and now it is ready to begin clinical development of a potential treatment that could be effective against emerging COVID-19 variants. ExeVir is not the first company to spin out of VIB to focus on camelid antibodies.

Antibody 98

Antibody Life Science Scientist Vaccination 98

pharmaphorum

AUGUST 23, 2021

The COVID-19 pandemic accelerated the development of mRNA-based vaccines, and its influence has now extended to DNA-based shots as well, with Zydus Cadila’s ZyCoV-D getting emergency use authorisation in India. The company also says that it can update the vaccine very easily to deal with mutations in the virus.

DNA 98

DNA Vaccination Vaccine Genetic Engineering 98

Drug Discovery World

DECEMBER 27, 2023

Developing. Ng is working on critical challenges in clinical trials, specifically in planning and recruitment, and has been building innovative solutions designed to benefit patients and researchers – with a focus on efficiency, transparency and diversity in clinical development. DDW Highlights Innovative. Listen here. Listen here.

Clinical Trials 69

Clinical Trials Clinical Trials Drugs Development 69

pharmaphorum

JUNE 4, 2021

At the moment, Xofigo is the only approved TAT on the market, but Bayer is also developing a pipeline of other candidates based on thorium-227 linked to antibodies or small-molecule drugs. The technology behind the drug was licensed from Weill Cornell Medicine and Johns Hopkins University in the US.

Antibody 58

Antibody Licensing Licensing Sales 58

pharmaphorum

JANUARY 18, 2022

Developing Complex, Translatable and Physiologically-Relevant Cellular Models in vitro. Explore the regulatory sciences surrounding Microphysiological systems, and their development and adoption for drug safety assessment. SMi’s 5th Annual 3D Cell Culture Conference. Virtual Conference: Online Access Only. 9-10 February 2022.

In-Vitro 52

In-Vitro Engineer Drugs Pharma Companies 52

pharmaphorum

FEBRUARY 24, 2021

The FDA has issued guidelines allowing for faster development of updated coronavirus vaccines, based on previously approved shots that have been tweaked to combat emerging variants of the SARS-CoV-2 virus. Manufacturers are also encouraged to study the response in previously vaccinated and unvaccinated people.

Vaccination 57

Vaccination Vaccine Immune Response Regulation 57